Business
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and
About this update from Immunome, Inc.
[{"type":"text","content":" EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today made an oral poster presentation on the company’s anti-interleukin-38 monoclonal antibody program at the joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.\n\nThe presentation highlighted that Immunome’s antibody:\n\n\nBinds to human IL-38 and inhibits binding to its putative receptors, IL1RAPL1 and IL-36R.\n\n\nInhibits IL-38-mediated suppression of myeloid cell activity in vitro.\n\n\nLeads to inhibition of tumor growth in two different murine syngeneic tumor models treated with the antibody and induces protection following implantation of secondary tumors.\n\n\n“Our data support the hypothesis that blockade of IL-38, which appears to act as an innate immune checkpoint, could reverse suppressive mechanisms in the tumor microenvironment and may contribute to the treatment of multiple cancers with high unmet need,” said Purnanand Sarma, PhD, President & CEO of Immunome. “Our compelling preclinical data demonstrate the power of Immunome's platform to identify novel anti-tumor targets, such as IL-38.”\n\nPresentation Details\n\nTitle: “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo.”\n\nAuthors: John P. Dowling, Pavel A. Nikitin, Fang Shen, James P. Finn, Nirja Patel, Cezary Swider, Jamie Steele, Halley Shukla, Matthew K. Robinson, Karen Lundgren & Benjamin C. Harman\n\nAbstract Number: LBA022\n\nDate/Time: All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021, at 9:00am E.T.\n\nAbout IL-38\n\nInterleukin-38 (IL-38) is a member IL-1 family cytokines and antagonizes multiple proinflammatory pathways through its putative receptors IL-36R, IL1RAPL1, and IL-1R1. Ablation of the IL-38 gene in multiple autoimmune diseases models leads to delayed resolution of inflammation and exacerbation of disease. On the contrary, treatment with recombinant IL-38 leads to amelioration of inflammation. IL-38 is expressed in multiple cancer cells, especially under apoptotic conditions1. In lung adenoc...